1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
HEAL Initiative: America's Startups and Small Businesses Build Technologies to Stop the Opioid Crisis (R43/R44 - Clinical Trial Optional) is sponsored by National Institute on Drug Abuse (NIDA) - NIH. HEAL Initiative: America's Startups and Small Businesses Build Technologies to Stop the Opioid Crisis (R43/R44 Clinical Trial Optional) is a grant from the National Institute on Drug Abuse (NIDA) at NIH that funds small business concerns to develop science-based technologies add…
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
A **. gov** website belongs to an official government organization in the United States.
* How to Apply for Grants * **Applicant Resources** * Adobe Software Compatibility * Submitting UTF-8 Special Characters * Encountering Error Messages * Grantor Standard Language * Submitting UTF-8 Special Characters * **Applicant System-To-System** * Reference Implementation * **Grantor System-To-System** * Reference Implementation * SF-424 Individual Family * SF-424 Mandatory Family * SF-424 Short Organization Family * Post-Award Reporting Forms * Country and State Lists Updates * **Manage Subscriptions** * Program Management Office * Grants.
gov Maintenance Calendar HEAL Initiative: Americas Startups and Small Businesses Build Technologies to Stop the Opioid Epidemic (R43/R44 - Clinical Trial Optional) Department of Health and Human Services National Institutes of Health Document Type:Grants Notice Funding Opportunity Number:RFA-DA-19-019 Funding Opportunity Title:HEAL Initiative: Americas Startups and Small Businesses Build Technologies to Stop the Opioid Epidemic (R43/R44 - Clinical Trial Optional) Opportunity Category:Discretionary Opportunity Category Explanation: Funding Instrument Type:Grant Category of Funding Activity:Education Expected Number of Awards: Assistance Listings:93.
279 -- Drug Abuse and Addiction Research Programs 93.
350 -- National Center for Advancing Translational Sciences Cost Sharing or Matching Requirement:No Last Updated Date:Dec 10, 2018 Original Closing Date for Applications:Sep 08, 2021 Current Closing Date for Applications:Sep 08, 2021 Archive Date:Oct 14, 2021 Estimated Total Program Funding:$ 7,000,000 Eligible Applicants:Small businesses Additional Information on Eligibility:Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
## Additional Information Agency Name:National Institutes of Health Description:This Funding Opportunity Announcement (FOA), issued by the National Institutes on Drug Abuse (NIDA), invites eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) grant applications to develop technologies to provide science- and research-based solutions to the national opioid crisis and offer new hope for individuals, families, and communities affected by this devastating crisis.
United States SBCs that have the research capabilities and technological expertise to contribute to NIDA R and D mission identified in this FOA are encouraged to submit SBIR grant applications in response to the FOA topics. Link to Additional Information:http://grants. nih.
gov/grants/guide/rfa-files/RFA-DA-19-019. html Grantor Contact Information:If you have difficulty accessing the full announcement electronically, please contact: If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster #### Health & Human Services * Frequently Asked Questions ## Your session will expire in 3 minutes. To continue working, click on the "OK" button below.
This is being done to protect your privacy. Unsaved changes will be lost.
According to the current listing, eligibility includes: Small businesses. United States SBCs that have the research capabilities and technological expertise to contribute to NIDA R&D mission. Confirm the full requirements in the official notice before applying.
The current listing shows normally may not exceed $306,872 for Phase I, and $2,045,816 for Phase II, unless proposal falls under one of the approved topics. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Applications for HEAL Initiative: America's Startups and Small Businesses Build Technologies to Stop the Opioid Crisis (R43/R44 - Clinical Trial Optional) are due April 5, 2027. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
HEAL Initiative: America's Startups and Small Businesses Build Technologies to Stop the Opioid Crisis (R43/R44 - Clinical Trial Optional) is funded by National Institute on Drug Abuse (NIDA) - NIH. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articlePA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read article